ClinicalTrials.gg
RecruitingNCT07792239Harbor-AFUpdated Aug 28, 2026

Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation

A Phase 2 interventional study of Budiodarone 200 mg BID and Budiodarone 400 mg BID in Atrial Fibrillation (AF) and Paroxysmal AF, sponsored by Xyra, LLC. Recruiting at 4 sites in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Xyra, LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 149 studies in Atrial Fibrillation with a site in Poland — 32 open to participants now, 45 under way, 2 of them phase 3. Atrial Fibrillation · Poland.

Planned enrollment
80th of 102
100 · median 327
Started
2026
with 6 others
Phase 2
16 of 149
4 open now
Primary completion
2027-06
later than 25 of 44 live
Registered
145th of 149
by date

Among the 149 studies in Atrial Fibrillation with a site in Poland, this one is the 80th largest by planned enrollment of the 102 interventional ones that give a count, is one of 7 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 25 of the 44 other live ones, and was the 145th registered.

Atrial Fibrillation

4,016 studies on the registry are indexed under Atrial Fibrillation; 964 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

32 of the 149 studies in Atrial Fibrillation with a site in Poland are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 610 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Atrial Fibrillation with a site in Poland, or all of them as a file.
02

Study summary

This multicenter, open-label study aims to assess the safety, tolerability and efficacy of budiodarone in treating participants with non-permanent AF, in particular paroxysmal atrial fibrillation (PAF). The trial will serve as a 6-month safety and a proof-of-concept study for a dose escalation strategy using AF monitoring, enrolling approximately 100 participants who will undergo 24 weeks of treatment. The study aims to evaluate the feasibility of dose escalation through AF monitoring of long episodes atrial fibrillation last 5 hours or longer.

Read the detailed description

The study will allow AF participants from three specific populations: 1) Participants with a pre-implanted Cardiac Implantable Electrical Device (CIED), which includes implantable pacemakers or implantable loop recorders (ILR) and who have a history of paroxysmal AF with LEAF lasting 5 hours or longer recorded in their pacemaker within the 3 months before screening; 2) Participants undergoing first-time elective electrical (direct current) cardioversion for persistent AF, or second-time elective electrical (direct current) cardioversion; and 3) Participants with paroxysmal AF who do not have a pacemaker or ILR and who have a history of frequent AF and LEAF, with a minimum CHA2DS2-VASc score of 1 or more for males and 2 or more for females.

AF monitoring will be conducted via a pre-implanted Cardiac Implantable Electrical Device (CIED), which includes implantable pacemakers or implantable loop recorders (ILR), for those who have one. Participants without a CIED will undergo AF monitoring using a cardiac patch and/or a wearable device on the wrist.

All participants who meet the study entry criteria will be started on 200 mg budiodarone BID. The participants will return to the study site every 4 weeks and dose adjustments will follow the following algorithm. If no AF episode lasting 5 hours or longer is recorded and no rolling 24-hour period shows a cumulative AF burden of 5 hours or longer, the participant is classified as a monthly responder, and the budiodarone dose remains unchanged. If at least one AF episode of 5 hours or longer is observed, or if any rolling 24-hour period indicates a cumulative AF burden of 5 hours or longer, the participant is designated as a monthly non-responder, and the budiodarone dose is increased by 200 mg BID up to a maximum of 800 mg BID.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Paroxysmal AF

Browse trials for

Keywords

  • AF
  • Atrial Fibrillation
  • Paroxysmal Atrial Fibrillation
  • PAF
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Proven paroxysmal atrial fibrillation or undergoing first-time elective electrical (direct current) cardioversion for persistent atrial fibrillation, or second-time elective electrical (direct current) cardioversion.
  • Baseline AF Criteria: To qualify for treatment, each participant must have during the 28-day baseline period an AFB greater than 5% and one of the following qualifying events: 1) 2 continuous AF episodes (LEAF) of 5 hours or longer; or 2) 2 rolling 24-hour periods in which cumulative AF duration is 5 hours or longer; or 3) 1 continuous AF episode (LEAF) of 5 hours or longer plus 1 rolling 24-hour period in which cumulative AF duration is 5 hours or longer
  • Must have failed at least one prior therapy for AF
  • Must have an AFSS greater than 3.
  • CHA₂DS₂-VASc score of 1 or more for males and 2 or more for females and be on oral anticoagulant for at least 3 weeks prior to receiving the study medication.
  • For participants with heart failure: Class I or II heart failure.

Key Exclusion Criteria:

  • NYHA Class 3 or 4 heart failure.
  • MI, ischemic stroke, or any venous thromboembolism within 3 months of screening.
  • Unstable angina, percutaneous transluminal coronary angioplasty (PTCA), or CABG within 3 months of screening.
  • Prolonged Interval with a normal QRS duration (>500 ms with QRS ≤120 ms).
  • Persistent AF (≥7 consecutive days or episodes >23 hours). Those presenting with persistent AF at screening are eligible if they are scheduled to undergo first-time elective cardioversion, or second-time cardioversion
  • Recent treatment with rhythm control medications (Class I or III Singh-Vaughan Williams) within five half-lives before screening (rate control drugs permitted) and amiodarone within 3 months prior to screening.
  • Cardiac ablation procedures within 30 days of screening or participants who have scheduled an ablation procedure
  • Severe end-organ disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Budiodarone

    Budiodarone is formulated as 200 mg capsules, to be administered as 1 capsule (200mg) twice a day (BID), 2 capsules (400 mg) BID, 3 capsules (600 mg) BID or 4 capsules (800 mg) BID.

    Drug: Budiodarone 200 mg BID · Drug: Budiodarone 400 mg BID · Drug: Budiodarone 600 mg BID · Drug: Budiodarone 800 mg BID

Interventions

  • DrugBudiodarone 200 mg BID

    Budiodarone is formulated as 200 mg capsules, to be administered as 1 capsule (200mg) twice a day (BID).

  • DrugBudiodarone 400 mg BID

    Budiodarone is formulated as 200 mg capsules, to be administered as 2 capsules (400 mg) BID.

  • DrugBudiodarone 600 mg BID

    Budiodarone is formulated as 200 mg capsules, to be administered as 3 capsules (600 mg) BID.

  • DrugBudiodarone 800 mg BID

    Budiodarone is formulated as 200 mg capsules, to be administered as 4 capsules (800 mg) BID.

06

What researchers measure

Primary outcomes

  1. Proportion of participants that have no long episodes of atrial fibrillation (LEAF) in the final month of treatment

    Proportion of participants that have no LEAF (uninterrupted episode of AF of 5 hours or longer in duration or cumulative duration of AF in any rolling 24-hour period that is 5 hours or longer) in the final month of treatment.

    Time frame: 24 weeks

Secondary outcomes

  1. Percent Change in Atrial Fibrillation Burden (AFB)

    Percent change in AFB during final month of treatment compared to baseline.

    Time frame: 24 weeks

  2. Change in percent of Atrial Fibrillation Severity Scale (AFSS) during final month of treatment.

    The University of Toronto Atrial Fibrillation Severity Scale (AFSS) is a patient-reported outcome instrument developed to quantify atrial fibrillation (AF). In this study, Part C of the scale will be used. In Part C, participants are asked to asses how AF symptoms affect daily activities, physical functioning, and overall quality of life. The minimum score is 0 and the maximum score is 35. Higher scores reflect greater impairment from AF-related symptoms. AFSS score during final month of treatment will be compared to baseline for multiple doses of budiodarone.

    Time frame: 24 weeks

  3. Patient Global Impression of Change (PGI-C) during the final month of treatment

    The Patient Global Impression of Change (PGI-C) is a two-question instrument that employs a Likert scale to assess participants' perceived changes in AF symptom control and overall satisfaction. Response options for symptom control include: Made them worse, No change, Slight improvement, Moderate improvement, A lot of improvement, and Complete relief. For overall satisfaction, participants choose from: Not at all, A little bit, Somewhat, A lot, and Completely.

    Time frame: 24 weeks

Other outcomes

  1. Safety Assessment

    Incidence of treatment-emergent adverse events (TEAE) and treatment-emergent serious adverse events (TESAE)

    Time frame: 24 weeks

  2. Safety Assessment

    Incidence of adverse events of special interest (AESI)

    Time frame: 24 weeks

  3. Safety Assessments

    Incidence of death

    Time frame: 24 weeks

  4. Safety Assessment

    Incidence of resuscitated sudden cardiac death

    Time frame: 24 weeks

  5. Safety Assessment

    Incidence of cardiovascular hospitalization

    Time frame: 24 weeks

  6. Safety Assessment

    Incidence of stroke

    Time frame: 24 weeks

  7. The proportion of participants with no LEAF episodes lasting one hour or longer in the final month of budiodarone treatment

    The proportion of participants with no LEAF episodes lasting one hour or longer in the final month of budiodarone treatment

    Time frame: 24 weeks

07

Study locations

4 of 4 sites recruiting
  • Oddział Kardiologiczny, Szpital Miejski Św. Wincentego a Paulo w Gdyni
    Gdynia, 81-348, Poland
    Recruiting
  • Klinika Kardiologii
    Krakow, 30-901, Poland
    Recruiting
  • EMED Centrum Usług Medycznych Ewa Śmiałek
    Rzeszów, 35-205, Poland
    Recruiting
  • Klinika Kardiologii i Chorób Wewnętrznych Wojskowy Instytut Medyczny, Państwowy Instytut Badawczy
    Warsaw, 04-141, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 10 months after the start.

Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Aug 28, 2026
StartActual
Aug 6, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07792239
Lead sponsor
Xyra, LLC
Collaborators
Amarex Clinical Research
Responsible party
Sponsor
First posted
Aug 28, 2026
Start date
Aug 6, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 28, 2026

Study contacts

Frederic Heerinckx@xyra.us
Contact
fheerinckx@xyra.us
+1 650 980-9972
Sherry Toney
Contact
stoney@xyra.us
+1 650 980-9972
Peter G Milner, MD, FACC
study director · Xyra, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion